Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on November 30, 2015. The report details the results of a special meeting of stockholders held on the same date at the company's offices in Madison, Wisconsin. The record date for the meeting was October 23, 2015.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and stockholder voting results.
Material Changes and Voting Results
A quorum was established with stockholders holding at least 3,782,067 shares present, out of 7,564,133 shares eligible to vote. Two proposals were presented:
- Proposal No. 1: Approval of the issuance of more than 20% of the company's common stock outstanding. This issuance relates to common stock issued on October 1, 2015, and the exercise of Series B pre-funded warrants and Series A warrants. This proposal was required under Nasdaq Marketplace Rule 5635(d) as the issuance was for less than the greater of book or market value.
- Proposal No. 2: Approval to adjourn the meeting to seek additional proxies if necessary. This vote was not taken as Proposal No. 1 was approved.
Voting Results for Proposal No. 1:
| Vote Type | Number of Shares |
|---|---|
| For | 4,437,554 |
| Against | 29,640 |
| Abstain | 5,612 |
| Broker Non-Votes | 187,102 |
The stockholders approved Proposal No. 1.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the regulatory requirement for stockholder approval of the equity issuance.
Key Facts for Investor Verification
- Stockholders approved the issuance of a significant equity block (over 20% of outstanding shares) related to October 1, 2015 transactions.
- The issuance involved common stock, Series B pre-funded warrants, and Series A warrants.
- The approval was necessary to comply with Nasdaq Marketplace Rule 5635(d) due to the issuance price being below book or market value.
- Proposal No. 2 regarding adjournment was rendered unnecessary by the approval of Proposal No. 1.